Synthetic Ecologies are defined cocktails of human-derived microbes, carefully designed for their ability to interact with other microbes and the host to drive clinical results.
Synthetic ecologies are distinct from existing microbial therapies
Synthetic ecologies represent a second generation of microbial therapy, unlike either traditional probiotics or first-generation natural microbial therapies.
Traditional probiotics are isolated from food products, not human donors, and as a result they are often poorly adapted to compete and engraft in the human microbiome.
First-generation natural microbial therapies like FIN-403 are based on processed fecal samples collected directly from human donors. With this approach, although the microbes are adapted to the gut microbiome, the intervention cannot be rationally designed and scaled.
Synthetic ecologies build on the well-characterized nature of probiotics and the physiological relevance of natural microbial therapies to create defined compositions of human-adapted, therapeutic microbes. By enabling the rational design of synthetic ecologies, we are opening the door to a new class of microbial therapy. FIN-524, a microbial cocktail for ulcerative colitis, is our first product candidate based on this philosophy.